Business Context and Reporting Period
Company: BioTime, Inc. (Note: Input metadata referenced Lineage Cell Therapeutics, but the filing text identifies BioTime, Inc.)
Reporting Period: Quarterly period ended September 30, 1996.
Status: Development stage enterprise engaged in R&D for synthetic plasma expanders (Hextend), blood substitutes, and organ preservation solutions. The company has not generated significant operating revenues and relies on equity financing.
Key Financial Metrics
| Metric | Q3 1996 | Q3 1995 | Inception to Sep 30, 1996 |
|---|---|---|---|
| Revenues | $20,163 | $44,178 | $749,495 |
| Total Expenses | $(738,519) | $(381,585) | $(9,532,322) |
| Net Loss | $(718,356) | $(337,407) | $(8,782,827) |
| Net Loss Per Share | $(0.26) | $(0.13) | $(4.43) |
| Cash and Equivalents (End of Period) | $2,019,144 | $2,860,706 | N/A |
| Net Cash Used in Operating Activities | $(583,842) | $(565,118) | $(8,458,459) |
| Net Cash Provided by Financing | $159,865 | $(14,420) | $10,475,759 |
| Accounts Payable | $173,591 | $129,229 | N/A |
Material Changes vs. Prior Period
- Expense Growth: Total expenses increased 93.5% year-over-year, driven by a 74% increase in Research & Development (R&D) and a 130% increase in General & Administrative (G&A) expenses.
- R&D Drivers: The increase in R&D is attributed to the preparation and initiation of Phase III human clinical trials for Hextend and a $25,000 expense for stock options granted to consultants.
- G&A Drivers: The increase in G&A is due to higher personnel costs and $45,413 in amortization expense related to warrants issued to financial advisors.
- Revenue Decline: Total revenue decreased 54% primarily due to lower interest income resulting from reduced cash balances.
- Cash Burn: Cash and cash equivalents decreased by approximately $424,000 during the quarter.
Outlook, Risks, and Management Commentary
- Clinical Progress: Phase III clinical trials for Hextend began in October 1996 at Duke University Medical Center. Additional studies for other surgical applications are being designed.
- Liquidity: Management estimates current cash reserves ($2.0 million) are sufficient to fund operations for approximately 9 months.
- Capital Needs: The company explicitly states that additional financing is required to complete clinical trials, prepare future IND filings, and potentially acquire production/marketing facilities.
- Financing Strategy: The company plans to seek funds through public/private equity or debt offerings and is negotiating with pharmaceutical companies for licensing or marketing rights.
- Risks: Continued losses are expected. Failure to secure adequate capital could force the company to curtail, delay, or suspend operations. Success depends on regulatory approvals and achieving sales levels to support the cost structure.
Investor Verification Checklist
- Verify the status and enrollment numbers of the Phase III clinical trials for Hextend initiated in October 1996.
- Confirm the timeline and terms of any pending equity or debt financing required to extend the 9-month runway.
- Review the specific terms of the financial advisory agreements and the vesting schedules of the 200,000+ warrants outstanding.
- Assess the progress of negotiations with pharmaceutical partners for manufacturing and marketing rights.
- Monitor the burn rate of cash relative to the projected costs of upcoming clinical studies.